BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Nordic AML Group - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nordic AML Group
X-ORIGINAL-URL:https://www.namlg.org
X-WR-CALDESC:Events for Nordic AML Group
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260303T160000
DTEND;TZID=Europe/Paris:20260303T170000
DTSTAMP:20260429T184609
CREATED:20251128T074113Z
LAST-MODIFIED:20251128T074113Z
UID:10000030-1772553600-1772557200@www.namlg.org
SUMMARY:NAMLG – Steering group meeting
DESCRIPTION:Agenda and meeting link will be sent via e-mail.
URL:https://www.namlg.org/event/namlg-steering-group-meeting-2/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260305T150000
DTEND;TZID=Europe/Paris:20260305T160000
DTSTAMP:20260429T184609
CREATED:20260304T002545Z
LAST-MODIFIED:20260304T002615Z
UID:10000036-1772722800-1772726400@www.namlg.org
SUMMARY:Germline Predisposition to Myeloid Neoplasms - Case discussions
DESCRIPTION:Join the MDR for patients with germline predisposition for hematological malignancies. \nThis meeting is for clinicians within the Nordics via this Zoom-link. \nIf you want to discuss a case\,  please send 1-2 summary slides with the most important information to Panagiotis Baliakas (panagiotis.baliakas@igp.uu.se)\, Uppsala\, Sweden. \n 
URL:https://www.namlg.org/event/germline-predisposition-to-myeloid-neoplasms-case-discussions/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260317T170000
DTEND;TZID=Europe/Paris:20260317T180000
DTSTAMP:20260429T184609
CREATED:20260216T121257Z
LAST-MODIFIED:20260216T121257Z
UID:10000035-1773766800-1773770400@www.namlg.org
SUMMARY:Webinar - Ask the expert: FLT3 MRD testing in AML patients
DESCRIPTION:Take the chance to join an Astellas Pharma sponsored webinar with Dr. Mark J. Levis\, MD\, PhD\, Baltimore\, USA\, entitled Ask the expert: FLT3 MRD testing in AML patients via Teams with the following agenda: \nAssess the current minimal residual disease testing modalities/methods\n Evaluate appropriate timing and efficacy of different FLT3 MRD testing modalities\n Summarize the appropriate treatment strategies in a post-transplant setting\n Best practice sharing in developing/setting up FLT3 MRD testing \nMore info and register here.
URL:https://www.namlg.org/event/webinar-ask-the-expert-flt3-mrd-testing-in-aml-patients/
END:VEVENT
END:VCALENDAR